Friday, July 10, 2026
🇺🇸 FDA

pharma · Prurigo Nodularis · Vitiligo

Incyte

Incyte clinical programs — 53 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
1801 Augustine Cut-Off, Wilmington, Delaware 19803, US HQ
3,381 Employees
NMPA registrant Type
Company details
Status
Public
HQ
1801 Augustine Cut-Off, Wilmington, Delaware 19803, US
Employees
3,381
Programs
53
Drugs
61
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Incyte projects

53 ClinicalTrials.gov programs sponsored by Incyte.

Incyte has 53 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

53 programs

Clinical programs

Page 1 of 2

  1. Axatilimab (INCA034176)

    Incyte

    Chronic Graft-Versus-Host Disease

    phase 3 small molecule active

    1 trial

  2. INCA033890-303

    Incyte

    Metastatic Microsatellite Stable Colorectal Cancer

    phase 3 small molecule active

    1 trial

  3. INCA34176-357

    Incyte

    chronic graft-versus-host disease

    phase 3 small molecule active

    1 trial

  4. INCB 18424-309

    Incyte

    Vitiligo

    phase 3 small molecule active

    1 trial

  5. INCB 18424-326

    Incyte

    Atopic Dermatitis

    phase 3 small molecule active

    1 trial

  6. INCB 54707-305

    Incyte

    Prurigo Nodularis

    phase 3 small molecule active

    1 trial

  7. INCB 54707-306

    Incyte

    Prurigo Nodularis

    phase 3 small molecule active

    1 trial

  8. INCB 54828-302

    Incyte

    Cholangiocarcinoma

    phase 3 small molecule active

    1 trial

  9. INCB018424-316

    Incyte

    Atopic Dermatitis

    phase 3 small molecule active

    1 trial

  10. INCB018424-324

    Incyte

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  11. INCB018424-325

    Incyte

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  12. INCB054707-801

    Incyte

    Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo

    phase 3 small molecule active

    1 trial

  13. INCB123667-305

    Incyte

    Ovarian cancer

    phase 3 small molecule active

    1 trial

  14. INCB18424-320

    Incyte

    Prurigo Nodularis

    phase 3 small molecule active

    1 trial

  15. INCMGA 0012-304

    Incyte

    Metastatic nonsquamous or squamous non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  16. INCMOR 0208-305

    Incyte

    Diffuse large B-cell lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  17. INCMOR0208-301

    Incyte

    follicular lymphoma (FL) and marginal zone lymphoma (MZL)

    phase 3 small molecule active

    1 trial

  18. MINJUVI 200 mg powder for concentrate for solution for infusion

    Incyte

    Immune-mediated thrombocytopenia, Autoimmune thrombocytopenia, Autoimmune hemolytic anemia

    phase 3 small molecule active

    1 trial

  19. MK-3475-669

    Incyte

    Histologically or cytologically-confirmed Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma that is considered incurable by local therapies

    phase 3 small molecule active

    1 trial

  20. MK-3475-679

    Incyte

    Locally advanced/metastatic renal cell carcinoma

    phase 3 small molecule active

    1 trial

  21. MOR208C310

    Incyte

    Newly-diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  22. Pembrolizumab

    Incyte

    Renal Cell Carcinoma (RCC)

    phase 3 small molecule completed

    1 trial

  23. Pemigatinib

    Incyte

    Unresectable Cholangiocarcinoma

    phase 3 small molecule terminated

    1 trial

  24. Placebo to Povorcitinib, Povorcitinib

    Incyte

    Vitiligo

    phase 3 small molecule active

    1 trial

  25. Povorcitinib

    Incyte

    Hidradenitis Suppurativa (HS)

    phase 3 small molecule completed

    1 trial

  26. Povorcitinib, Placebo to Povorcitinib

    Incyte

    Vitiligo

    phase 3 small molecule active

    1 trial

  27. Povorcitinib, Povorcitinib

    Incyte

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  28. Retifanlimab (INCMGA00012) for Squamous Carcinoma of the Anal Canal

    Incyte

    Squamous Carcinoma of the Anal Canal

    phase 3 small molecule active

    1 trial

  29. Rituximab (RTX)

    Incyte

    Diffuse Large B-cell Lymphoma

    phase 3 small molecule completed

    1 trial

  30. Axatilimab (INCA034176)

    Incyte

    Chronic Graft-Versus-Host Disease

    phase 2 small molecule active

    1 trial

  31. INCA34176-254

    Incyte

    chronic graft-versus-host disease

    phase 2 small molecule active

    1 trial

  32. INCAGN 2385-203

    Incyte

    In participants with PD-L1–positive and systemic therapy–naive R/M SCCHN.

    phase 2 small molecule active

    1 trial

  33. INCB 00928-104

    Incyte

    Anaemia associated with myelofibrosis

    phase 2 other active

    1 trial

  34. INCB 54707-208

    Incyte

    Treatment of patients with inadequately controlled moderate to severe asthma

    phase 2 small molecule active

    1 trial

  35. INCB 84344-102

    Incyte

    Recurrent or Refractory Leukemias, Lymphomas, and Solid Tumors

    phase 2 small molecule active

    1 trial

  36. INCB000928, Placebo

    Incyte

    Fibrodysplasia Ossificans Progressiva

    phase 2 small molecule active

    1 trial

  37. INCB099280, Adagrasib

    Incyte

    Advanced Solid Tumors Harboring a KRASG12C Mutation

    phase 2 small molecule active

    1 trial

  38. INCB123667-203

    Incyte

    Ovarian Cancer

    phase 2 other active

    1 trial

  39. INCMGA0012-204

    Incyte

    Endometrial cancer, Endometrial cancer

    phase 2 small molecule active

    1 trial

  40. Jakavi 5 mg tablets, Jakavi 15 mg tablets

    Incyte

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  41. MOR208C115

    Incyte

    Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 small molecule active

    1 trial

  42. Parsaclisib

    Incyte

    Lymphoma

    phase 2 small molecule completed

    1 trial

  43. Pembrolizumab

    Incyte

    Lung Cancer

    phase 2 small molecule completed

    2 trials

  44. INCA 33989-101

    Incyte

    Myeloproliferative Neoplasms

    phase 1 other active

    1 trial

  45. INCA33890

    Incyte

    Solid Tumors

    phase 1 small molecule active

    1 trial

  46. INCB 123667-101

    Incyte

    Advanced or metastatic solid tumors

    phase 1 other active

    1 trial

  47. INCB 161734-101

    Incyte

    Advanced or metastatic solid tumors

    phase 1 other active

    1 trial

  48. INCB 57643-103

    Incyte

    Treatment of participants with MF, MDS, ET, or MDS/MPN

    phase 1 other active

    1 trial

Frequently asked questions

How many clinical projects does Incyte have?

53 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.